Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine

S. J. Cryz, H. Goldstein, M. Pettoello-Mantovani, A. Kim, E. Fürer, J. U. Que, T. Hasler, A. Rubinstein

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


To enhance the potential efficacy of peptide-based vaccines for human immunodeficiency virus-1 (HIV-1), a principal neutralizing domain (PND) peptide (KRIHIGPGRAFYT) (HIV-1MN) was covalently coupled to Pseudomonas aeruginosa toxin A (TA). Immunization of guinea-pigs with this conjugate vaccine, in the absence of an adjuvant, engendered a high-affinity antibody response to the homologous HIV-1MN PND peptide and to analogous peptides from variant strains of HIV-1. A substantial proportion of such antibodies was directed to the conserved GPGRAF motif. Anti-PND peptide antibodies were capable of neutralizing the homologous strain, HIV-1MN, in addition to two heterologous (RF, IIIB) variants, as determined either by inhibition of syncytia formation or by suppression of p24 antigen production in cultured cells. Therefore, the method of conjugation used preserved critical neutralizing epitopes expressed by the PND peptide. Monovalent or polyvalent PND-TA conjugates, which meet all safety criteria for human use, are a promising approach towards the development of an acquired immunodeficiency syndrome (AIDS) vaccine.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
Issue number1
StatePublished - Jan 1995


  • Human immunodeficiency virus-1
  • peptide-toxin A conjugate
  • principal neutralizing domain

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine'. Together they form a unique fingerprint.

Cite this